Cybin reports first quarter financial results and recent business highlights

Toronto--(business wire)--cybin inc. (nyse american:cybn) (neo:cybn) (“cybin” or the “company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today reported unaudited financial results for its first quarter ended june 30, 2023, and recent business highlights. “the steady clinical progress we have made over the past few months is truly encouraging, with dosing initiated in the final.
CYBN Ratings Summary
CYBN Quant Ranking